Evidence map›Paper›PMID 33088687›Full record

ArticleActa pharmaceutica Sinica. B2020

First small-molecule PROTACs for G protein-coupled receptors: inducing

Zhenzhen Li, Yuxing Lin, Hui Song, Xiaojun Qin, Zhongxia Yu, Zheng Zhang, Gaopan Dong, Xiang Li, Xiaodong Shi, Lupei Du and 2 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta pharmaceutica Sinica. B, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 49 citations in OpenAlex.

  1. Review
  2. Induced proximity-based therapeutic modalities.Nature reviews. Drug discovery · 2026
    Review
  3. Article
  4. Article
  5. The function of GPCRs in different bone cells.International journal of biological sciences · 2025
    Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Cereblon: promise and challenges for combating human diseases.Pflugers Archiv : European journal of physiology · 2021
    Review
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 2 countries.

Zhenzhen LiDepartment of Medicinal Chemistry, Key Laboratory of Chemical Biology (MOE), School of Pharmacy, Shandong University, Jinan 250012, China.
Yuxing LinDepartment of Medicinal Chemistry, Key Laboratory of Chemical Biology (MOE), School of Pharmacy, Shandong University, Jinan 250012, China.
Hui SongDepartment of Immunology, Key Laboratory of Infection and Immunity of Shandong Province, School of Basic Medical Science, Shandong University, Jinan 250012, China.
Xiaojun QinDepartment of Medicinal Chemistry, Key Laboratory of Chemical Biology (MOE), School of Pharmacy, Shandong University, Jinan 250012, China.
Zhongxia YuDepartment of Immunology, Key Laboratory of Infection and Immunity of Shandong Province, School of Basic Medical Science, Shandong University, Jinan 250012, China.
Zheng ZhangDepartment of Medicinal Chemistry, Key Laboratory of Chemical Biology (MOE), School of Pharmacy, Shandong University, Jinan 250012, China.
Gaopan DongDepartment of Medicinal Chemistry, Key Laboratory of Chemical Biology (MOE), School of Pharmacy, Shandong University, Jinan 250012, China.
Xiang LiDepartment of Medicinal Chemistry, Key Laboratory of Chemical Biology (MOE), School of Pharmacy, Shandong University, Jinan 250012, China.
Xiaodong ShiDepartment of Chemistry, University of South Florida, Tampa, FL 33620, USA.
Lupei DuDepartment of Medicinal Chemistry, Key Laboratory of Chemical Biology (MOE), School of Pharmacy, Shandong University, Jinan 250012, China.
Wei ZhaoDepartment of Immunology, Key Laboratory of Infection and Immunity of Shandong Province, School of Basic Medical Science, Shandong University, Jinan 250012, China.
Minyong LiDepartment of Medicinal Chemistry, Key Laboratory of Chemical Biology (MOE), School of Pharmacy, Shandong University, Jinan 250012, China.
Shandong University · CNState Key Laboratory of Microbial TechnologyUniversity of South Florida · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Proteolysis targeting chimeras (PROTACs) are dual-functional hybrid molecules that can selectively recruit an E3 ubiquitin ligase to a target protein to direct the protein into the ubiquitin-proteasome system (UPS), thereby selectively reducing the target protein level by the ubiquitin-proteasome pathway. Nowadays, small-molecule PROTACs are gaining popularity as tools to degrade pathogenic protein. Herein, we present the first small-molecule PROTACs that can induce the

Indexed as

BPH, benign prostatic hyperplasiaCRBN, cereblonDCM, dichloromethaneDegradationDMF, dimethylformamideDMSO, dimethylsulfoxideGPCR, G-protein-coupled receptorhPCE, human prostate cancer epithelialHPLC, high-performance liquid chromatographyLUTS, lower urinary tract symptomsProstate cancerPROTACs, proteolysis targeting chimerasSmall-molecule PROTACsTEA, triethylamineTHF, tetrahydrofuranUbiquitylationα1A-Adrenergic receptorα1A-AR, α1A-adrenergic receptorα1-ARs, α1-adrenergic receptorsα1B-AR, α1B-adrenergic receptorα1D-AR, α1D-adrenergic receptor

Identifiers

PMID33088687
PMCPMC7563999
OpenAlexW3002542796

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.